Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinoma.
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2015
At a glance
- Drugs Amrubicin (Primary) ; Carboplatin (Primary)
- Indications Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 12 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 15 Mar 2011 New trial record